Announcement PDF ATOMO DIAGNOSTICS Q3 RESULTS & INVESTOR PRESENTATION 28 APRIL 2026 INTRODUCTION Investor Overview • APRIL 2026 Atomo is an innovative diagnostics company with unique products in the point-of-care (POC) test market ATOMO DIAGNOSTICS LIMITED | ASX: AT1 W H O I S A T O M O ? A T O M O ’ S S T R A T E G I C F O C U S ? We develop, manufacture & supply innovative rapid diagnostic tests, including Self-tests to international markets Best-in-class usability, acceptability and performance — increasingly recognised as delivering unmatched simplicity and reliability in point-of-care testing Significant growth opportunity as Atomo expands its rapid test portfolio and demand for its proprietary test cassettes grows Point of Care Diagnostics Tests – Building a high value portfolio: HIV – Commercially launched: recognised market leader in ANZ and UK Active Syphilis – unique test that can distinguish active & prior treated Syphilis in a POC format (In-Development) Partner Supply – Critical Supply of Pascal Proprietary Cassettes: Supply to Lumos Diagnostics for their FDA CLIA waived FebriDx® test We are a trusted critical supply partner to diagnostic companies utilising our unique device usability to secure high value product registrations and access large markets Liver Function – an easy-to-use test to diagnose liver damage common with several chronic diseases (In Development) ASX: AT1 Supply to NG Biotech for their European IVDR approved Blood pregnancy Building a customer base that increasingly recognises the value of reliability, with two new customers recently secured ® Investor Overview • APRIL 2026 ATOMO DIAGNOSTICS LIMITED | ASX: AT1 ASX: AT1 Q3 ACTIVITY HIGHLIGHTS JAN FEB MAR APR HIV order for Africa - $500k LMIC US FDA CLIA Waiver Secured for FebriDx A$3m Capital Raise Completed Two new international customers secured for Pascal supply 2nd HIV order for Africa - $410k LMIC Large HIV order from NAPWHA, $630k ANZ Exclusive Global License secured for novel Liver Test • Lumos’ FebriDx® receives CLIA waiver approval from the US FDA • unlocks material growth in the US market for Pascal supply for FebriDx® • provides predicate pathway to US market for Atomo’s diagnostic test products • validates a material market expansion opportunity for new customers on Pascal • Sales orders worth more than $2 million received during the quarter Investor Overview • APRIL 2026 ATOMO DIAGNOSTICS LIMITED | ASX: AT1 ASX: AT1 APPENDIX 4C OVERVIEW In accordance with ASX Listing Rule 4.7C.3, Atomo advises that an amount of $148k was paid during the quarter covering Atomo’s Managing Director salary and Non-Executive Directors fees. - 0.50 1.00 1.50 2.00 Comparative Qrt Q3 FY25 Previous Qrt Q2 FY26 Current Qrt Q3 FY26 HIV OEM Development & other (2.0) (1.5) (1.0) Comparative Qrt Q3 FY25 Previous Qrt Q2 FY26 Current Qrt Q3 FY26 OPEX Investor Overview • APRIL 2026 ATOMO DIAGNOSTICS LIMITED | ASX: AT1 ASX: AT1 Q3 FINANCIAL HIGHLIGHTS (3.0) (2.5) (2.0) (1.5) (1.0) (0.5) 0.0 0.5 1.0 1.5 2.0 Comparative Qrt Q3 FY25 Previous Qrt Q2 FY26 Current Qrt Q3 FY26 A$M Cash Receipts Other Receipts (rebate/grants & cap. Rasie) Cash outflows CASH FLOW ACTIVITIES REVENUE & OPERATING EXPENSES • Cash on hand as at Q3 FY26 finished on $2.6m and debt-free • Cash receipts for the quarter totaled $1.8m made up of $1.6m customer receipts and $165k from the on-going Syphilis CRC-P development grant • Cash outflows totaled $2.6m for the quarter, reflecting continued investment in program delivery, product supply and efforts progressing new programs and development opportunities • Overall, for the quarter expenses totaled $1.8m • Operating expenses continues to be managed and deployed towards strategic growth opportunities • This does note take into account other income from CRC-P grant and government R&D rebates, further improving bottom line by ~15- 20% • Revenue of $814k, bringing YTD revenue to ~$3m (up 4% comparable YTD period) • OEM ~$495k: increased orders for Pascal from FebriDx • HIV ~$270k sales • Additional orders received during the period >$2 million INVESTOR PRESENTATION ASX: AT1 INVESTMENT HIGHLIGHTS ASX: AT1 Investment Highlights • APRIL 2026 Innovating novel and disruptive lateral flow solutions in point-of-care and self-test ATOMO DIAGNOSTICS LIMITED | ASX: AT1 Direct participation in multiple growing, high-volume diagnostic markets with Atomo’s finished tests that offer excellent ease-of-use & performance – HIV, Syphilis, Liver Function and others Global commercial market footprint established – sales channels into Australian, US, European, Asian and African markets Innovative patented proprietary technology that is proven to deliver a level of user reliability, performance and acceptability unmatched in decentralised settings Pascal enabled FDA CLIA waiver of Lumos’ FebriDx® provides step-change for Atomo, by; • unlocking significant growth in the US market for Pascal supply for FebriDx® • providing a predicate pathway to US market for Atomo’s diagnostic test products • validating a valuable market expansion opportunity via Pascal for new customers Revenue Operating Discipline EBITDA Productive Assets FY25 REVENUE A$3.8M ✓ Atomo is seeing strong momentum in its established revenue channels including HIV Tests and Pascal Cassettes ✓ Expansion of customer base across new products pipeline and new partners for Atomo cassettes STRONG GROWTH TARGETED FY26 ✓ Capital focus on new test portfolio development / commercialisation – Syphilis, Liver etc/ ✓ Non-dilutive funding grants (Syphilis) and selective licensing of proven assets (Liver) used to support low-cost development and go to market (3.0) (2.0) (1.0) 0.0 H1 FY24 H2 FY24 H1 FY25 H2 FY25 H1 FY26 A$(m) Historical EBITDA ✓ EBITDA trending towards breakeven as existing revenue channels grow and product offerings expand ✓ Clean debt free balance sheet ✓ Atomo validating a second- generation blister machine and high-cavity mould tooling to support expansion of capacity and improve economies of scale FINANCIAL SUMMARY ASX: AT1 Investment Highlights • APRIL 2026 ATOMO DIAGNOSTICS LIMITED | ASX: AT1 EXTENSIVE IP & PRODUCT REGISTRATIONS ASX: AT1 IP & Registrations • APRIL 2026 7 patent families and extensive proprietary know-how across 30+ countries — underpinning a defensible competitive position ATOMO DIAGNOSTICS LIMITED | ASX: AT1 P A T E N T F A M I L I E S Family 1 Diagnostic System PCT/AU2011/000315 Family 2 Sampling Assembly PCT/AU2011/001321 Family 3 Fluid Control Integrated Testing Devices PCT/IB2014/066210 Family 4 Integrated Fluid Module PCT/AU2016/051134 Family 5 Integrated Blood Testing Device PCT/AU2018/051114 Family 6 Pre-Mix Test Vessel PCT/AU2022/050812 Family 7 Automated Verification & Guidance PCT/AU2022/051076 P R O D U C T R E G I S T R A T I O N S Atomo HIV Self-Test TGA — Australia WHO PQ — LMIC CE Mark — UK & Europe Pascal enabled Pregnancy Test CE Mark — UK & Europe ANVISA — Brazil Pascal enabled FebriDx® FDA 510k & CLIA Waiver — US CE Mark — UK & Europe TGA — Australia Product Pipeline • APRIL 2026 ASX: AT1 Building a portfolio of innovative point-of-care rapid diagnostic tests for global markets PRODUCT INDICATION DEVELOPMENT VALIDATION & REGULATORY APPROVAL LAUNCH LAUNCHED HIV HIV Detection (Self-Testing) ● LAUNCHED – ANZ, UK & LMIC HIV Detection (Professional Use) ● APPROVED – OPPORTUNITY FOR GEN IV UPGRADE Market ready Pregnancy Pregnancy Detection (Self & Professional) ● LAUNCHING – Europe. ATOMO MARKETS TO FOLLOW PIPELINE Syphilis Distinguish active vs prior treated infection DEVELOPMENT COMPLETE – CLINICAL TRIALS COMMENCING 2026 PIPELINE Liver / ALT Liver disease screening & monitoring TEST DEVELOPMENT COMPLETE – CLINICAL GO TO MARKET DEVELOPMENT COMMENCED TESTS UNDER CONSIDERATION PSA Prostate cancer screening Stroke Acute neurological triage Coeliac Gluten sensitivity detection HIV Gen 4 4th generation HIV detection Others TBD Subject to commercial assessment ATOMO DIAGNOSTICS LIMITED | ASX: AT1 EXPANDING TEST PORTFOLIO HIV SELF-TEST — MARKET OPPORTUNITY ASX: AT1 HIV Momentum • APRIL 2026 Consistent order flow from established channels supports sustained growth in HIV revenues A$200M SOM* * Global excl. US HIV Self-Test Serviceable Obtainable Market Estimate 10% CAGR Self-Test Market growth rate HIV Self-Test orders received YTD FY26 EUROPE & REST OF WORLD EXPANSION AND SUSTAINABILITY ATOMO DIAGNOSTICS LIMITED | ASX: AT1 250,000+ Tests Estimated at-home testing market in UK via public health 8 European Countries Active pipeline via Newfoundland Diagnostics ~500k Tests Ordered via the Global Fund during FY26 Scalable Commercial Model Proven ANZ market creation strategy applied globally — prioritising funded markets, established procurement systems, and higher-margin regions with registration. Established in BOOTS and Tesco in UK Pharmacy/retail and public health demand Expansion across Western & Northern Europe Active discussions with national distributors Leverage TGA and WHO Prequalification Prioritising commercially viable markets Selective market access via Viatris partnership Integration into donor-funded & public programmes High-volume scale contingent on funding support Europe APAC Global Health * SOM = Serviceable Obtainable Market, value estimated by Atomo based on 2025 data HIV SELF-TEST – ANZ BUSINESS ASX: AT1 Transitioning from Proven Revenue to Scalable Global Expansion ATOMO DIAGNOSTICS LIMITED | ASX: AT1 First to scale a national pharmacy-based HIV self-testing model Leading HIV self-test provider in ANZ pharmacy retail Additional access: Online channels & Chemist Warehouse NZ Pharmacy Expansion — 600+ new rollout opportunity Channel Expansion — Adult retail, specialty channels, online marketplace, NZ growth Public Health Scale-Up — Potential Government & NGO programs and recurring volume Current Position 12-Month Growth Plan Atomo has successfully created and leads the HIV self-testing market in ANZ, with a clear and executable pathway to scale further through pharmacy expansion, channel diversification, and increased public health procurement T W O K E Y G R O W T H D R I V E R S Retail Market Growth Atomo has created the pharmacy HIV self-testing model in ANZ and is now scaling it nationally through expanded ranging across all national chains, increased shelf presence, and repeat testing behaviors Public Health Procurement Established pilot programs now adopted through public health procurement providing a strong volume foundation, with Atomo positioned to scale into expanding national programs as governments accelerate self-test adoption A$8M SOM* ANZ HIV Self-Test – Serviceable Obtainable Market Estimate > 85% Australian HIV Self-Test Market Share NSW Health Vending Machine * SOM = Serviceable Obtainable Market, value estimated by Atomo based on 2025 data ACTIVE SYPHILIS – HIGH-LEVERAGE EXPANSION ASX: AT1 Active Syphilis • APRIL 2026 • no existing rapid test can reliably distinguish active & prior infection • no current test format is optimised for easy, reliable self-testing ATOMO DIAGNOSTICS LIMITED | ASX: AT1 Atomo plans to leverage existing HIV commercial infrastructure, partnerships and sales channels to enable rapid, capital-efficient market entry 1.6M UK Syphilis Tests in 2024 * Established demand existing HIV Channels Channel Leverage — Similar users, procurement bodies, and distribution channels as HIV testing Immediate Commercialisation — Deployable alongside existing HIV test programs Efficiency — Lower cost of entry, faster time to launch and scale revenue Market Drivers Funded public health programmes Community & decentralised testing Increasing adoption of self-testing Verification Complete Strong product development and verification data Clinical Trials Commencing Progressing toward commercialisation Regulatory Engagement Positive engagement with regulators and stakeholders Dual Pathway Professional use and self-testing channels ready Development & Readiness Addressing significant unmet clinical and market needs • https://www.gov.uk/government/publications/tracking-the-syphilis-epidemic- in-england/tracking-the-syphilis-epidemic-in-england-2015-to-2024 UNIQUE LIVER TEST – BROAD OPPORTUNITY ASX: AT1 Liver Test • APRIL 2026 • Multiple large addressable markets across chronic disease management, drug safety and at-risk population screening • Global license secured from Burnet Institute with development substantially complete and good performance established ATOMO DIAGNOSTICS LIMITED | ASX: AT1 01 Drug-Induced Liver Injury (DILI) Monitoring for common drug types requiring ALT surveillance — TB drugs, Methotrexate, Leflunomide, Azathioprine, Valproate, Amiodarone, long-term Diclofenac. Evaluation underway in US trial by multinational pharmaceutical company 02 Hepatitis B & C Management Diagnosis and treatment management — evaluation trial planned to assess use in determining commencement of Hepatitis B drug treatment based on ALT level. 03 Fatty Liver Disease Screening High correlation between elevated ALT and fatty liver disease — affecting 1.5B+ people globally. Significant opportunity for home screening and monitoring of at-risk and diagnosed patients. 04 Alcoholic Liver Disease Screening Elevated ALT is a key early indicator of alcohol-related liver cell injury and inflammation — enabling immediate home screening across the 300 million people affected globally. Drug-Induced Liver Injury (DILI) 2025 SOM - A$72M 2032 SOM – A$100M Hepatitis B & C Management 2025 SOM - A$53M 2032 SOM – A$86M Fatty Liver Disease 2032 SOM – A$80M Alcoholic Liver Disease 2032 SOM – A$25M * SOM = Serviceable Obtainable Market, value estimated by Atoo based on 2025 data PARTNERING BUSINESS — FY26 HIGHLIGHTS ASX: AT1 Pascal OEM • APRIL 2026 Transformational growth anticipated with Pascal revenues; CLIA waiver of Lumos’ test in the US drives step-change in demand and increases visibility in market ATOMO DIAGNOSTICS LIMITED | ASX: AT1 > 99% Concordance between trained and untrained users of Pascal FebriDx in US CLIA waiver study US$313m Lumos anticipated FebriDx revenue over contract term > 99% ~1,600% increase in Pascal FebriDx orders in H1 FY26 vs H1 FY25 — reflecting commercial adoption of the Pascal platform following US clinical validation Lumos six-year agreement with PHASE Scientific — FebriDx product revenues of up to US$313m anticipated over the term based on CLIA waiver & contracted MOQs Lumos’ FebriDx® secures US FDA CLIA waiver approval - CLIA waiver expands the US addressable by around 15 times to over US$1 billion* Each FebriDx test sold generates a Pascal cassette order — Atomo receives a portion of the transfer price, creating a direct and scalable revenue link to FebriDx sales Growing pipeline of Pascal customers across high value diagnostic applications — additional international customers (UK and Canada) recently secured * Doug Ward – CEO, Lumos Diagnostics https://www.proactiveinvestors.com/companies/ news/1076809/lumos-diagnostics-submits-clia- waiver-application-for-febridx-1076809.html EXPANDING OPERATIONAL CAPABILITIES ASX: AT1 Operations • APRIL 2026 Scaling infrastructure to support growing demand for Atomo Tests and Test Cassettes ATOMO DIAGNOSTICS LIMITED | ASX: AT1 • Outsourced US operations for blister production in PA • Pascal Supplied to Lumos in California NORTH AMERICA • Atomo South Africa facility – assembly of HIV Tests (Syphilis planned) SOUTH AFRICA • Atomo HIV ST supplied to Newfoundland in UK and now Europe • Pascal Supplied to NG Biotech in France EUROPE • Outsourced cassette moulding / assembly CHINA • Headquarters: • Innovation Centre & Blister Manufacturing • Direct to market HIV distribution with established brand recognition AUSTRALIA INVESTMENT HIGHLIGHTS ASX: AT1 Investment Highlights • APRIL 2026 Innovating novel and disruptive lateral flow solutions in point-of-care and self-test ATOMO DIAGNOSTICS LIMITED | ASX: AT1 Direct participation in multiple growing, high-volume diagnostic markets with Atomo’s finished tests that offer excellent ease-of-use & performance – HIV, Syphilis, Liver Function and others Global commercial market footprint established – sales channels into Australian, US, European, Asian and African markets Innovative patented proprietary technology that is proven to deliver a level of user reliability, performance and acceptability unmatched in decentralised settings Pascal enabled FDA CLIA waiver of Lumos’ FebriDx® provides step-change for Atomo, by; • unlocking significant growth in the US market for Pascal supply for FebriDx® • providing a predicate pathway to US market for Atomo’s diagnostic test products • validating a valuable market expansion opportunity via Pascal for new customers Rule 4.7B Name of Entity Atomo Diagnostics Limited ABN Quarter Ended ("current quarter") 31 March 2026 Consolidated statement of cash flows Current Quarter Year to date (9 months) A$'000 A$'000 1. Cash flows from operating activities 1.1 Receipts from customers 1,572 3,553 1.2 Payments for (a) research and development ( 445) ( 568) (b) product manufacturing and operating costs ( 1,088) ( 3,134) (c) advertising and marketing ( 25) ( 126) (d) leased assets - - (e) staff costs ( 667) ( 1,991) (f) administration and corporate costs ( 321) ( 909) 1.3 Dividends received (see note 3) - - 1.4 Interest received 17 51 1.5 Interest and other costs of finance paid - - 1.6 Income taxes paid - - 1.7 Government grants and tax incentives 165 1,370 1.8 Other (provide details if material) 1.9 Net cash from / (used in) operating activities ( 792) ( 1,755) 2. Cash flows from investing activities 2.1 Payments to acquire or for: (a) entities - - (b) businesses - - (c) property, plant and equipment 5 ( 41) (d) investments - - (e) intellectual property 0 0 (f) other non-current assets - Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B 37 142 925 684 ASX Listing Rules Appendix 4C (17/07/20) + See chapter 19 of the ASX Listing Rules for defined terms. Page 1 Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B Consolidated statement of cash flows Current Quarter Year to date (9 months) A$'000 A$'000 2.2 Proceeds from disposal of: (a) entities - - (b) businesses - - (c) property, plant and equipment - - (d) investments - - (e) intellectual property - - (f) other non-current assets - - 2.3 Cash flows from loans to other entities - - 2.4 Dividends received (see note 3) - - 2.5 Other (provide details if material) - - 2.6 Net cash from / (used in) investing activities 5 ( 41) 3. Cash flows from financing activities 3.1 Proceeds from issues of equity securities (excluding convertible debt securities) 40 1,404 3.2 Proceeds from issue of convertible debt securities - - 3.3 Proceeds from exercise of options - 3.4 Transaction costs related to issues of equity securities or convertible debt securities ( 1) ( 65) 3.5 Proceeds from borrowings - - 3.6 Repayment of borrowings ( 68) ( 176) 3.7 Transaction costs related to loans and borrowings - 3.8 Dividends paid - 3.9 Other (provide details if material) - 3.10 Net cash from / (used in) financing activities ( 29) 1,162 4. Net increase / (decrease) in cash and cash equivalents for the period 4.1 Cash and cash equivalents at beginning of period 3,512 3,220 4.2 Net cash from / (used in) operating activities (item 1.9 above) ( 792) ( 1,755) 4.3 Net cash from / (used in) investing activities (item 2.6 above) 5 ( 41) ASX Listing Rules Appendix 4C (17/07/20) + See chapter 19 of the ASX Listing Rules for defined terms. Page 2 Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B Consolidated statement of cash flows Current Quarter Year to date (9 months) A$'000 A$'000 4.4 Net cash from / (used in) financing activities (item 3.10 above) ( 29) 1,162 4.5 Effect of movement in exchange rates on cash held ( 90) 18 4.6 Cash and cash equivalents at end of period 2,605 2,605 5. Reconciliation of cash and cash Current Quarter Previous Quarter equivalents A$'000 A$'000 at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts 5.1 Bank balances 2,605 3,512 5.2 Term deposits - - 5.3 Bank overdrafts - - 5.4 Other (provide details) - - 5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above) 2,605 3,512 6. Payments to related parties of the entity and their Current Quarter associates A$'000 6.1 148 6.2 - Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments. Aggregate amount of payments to related parties and their associates included in item 2 Aggregate amount of payments to related parties and their associates included in item 1 ASX Listing Rules Appendix 4C (17/07/20) + See chapter 19 of the ASX Listing Rules for defined terms. Page 3 Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B 7. Financing facilities Total facility Amount drawn at Note: the term "facility" includes all forms of financing amount at quarter quarter arrangements available to the entity. end end Add notes as necessary for an understanding of the A$'000 A$'000 sources of finance available to the entity 7.1 Loan facilities - - 7.2 Credit standby arrangement - - 7.3 Other (please specify) - - 7.4 Total financing facilities - - 7.5 Unused financing facilities available at quarter end - 7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well. 8. Estimated cash available for future operating activities A$'000 8.1 Net cash from / (used in) operating activities (Item 1.9) ( 792) 8.2 Cash and cash equivalents at quarter end (Item 4.6) 2,605 8.3 Unused finance facilities available at quarter end (Item 7.5) - 8.4 Total available funding (Item 8.2 + Item 8.3) 2,605 8.5 Estimated quarters of funding available (item 8.4 divided by 3.30 item 8.1) 8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions: 1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not? Answer: Not applicable. 2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful? Answer: Not applicable. 3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis? Answer: Not applicable. ASX Listing Rules Appendix 4C (17/07/20) + See chapter 19 of the ASX Listing Rules for defined terms. Page 4 Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B Compliance statement 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A. 2 This statement gives a true and fair view of the matters disclosed. Date: 28 April 2026 (Name of body or officer authorising release see note 4) Notes 1. 2. 3. 4. 5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively. Authorised by: ..........The Board This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity. If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”. If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the [name of board committee – eg Audit and Risk Committee] ”. If it has been authorised for release to the market by a disclosure committee, you can insert here: “By the Disclosure Committee”. ASX Listing Rules Appendix 4C (17/07/20) + See chapter 19 of the ASX Listing Rules for defined terms. Page 5